Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus

What Was Tested

This randomized controlled trial paper looks at Exenatide.

Who Took Part

The age groups tagged for this paper are teenagers, adults, middle-aged adults and older adults, both men and women.

Treatment with oral antidiabetic agents was stopped 14 days before study initiation.

Parts 1 and 2 of study B enrolled six and eight patients, respectively.

How the Study Was Run

The researchers set it up as a randomized, single-blind and placebo-controlled study.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Only one side, usually the participants, was kept unaware of whether Exenatide was given.

A placebo (an inactive look-alike) gave the Exenatide group a baseline to be compared against.

Two randomized, single-blind, placebo-controlled studies were conducted.

After an overnight fast, the study drug was injected 15 minutes before a meal (part 1) and before a meal and acetaminophen (part 2).

What Was Measured

PubMed files the paper under topics including Area Under Curve, Blood Glucose, Diabetes Mellitus, Type 2, Exenatide, Gastric Emptying, Glucagon and Insulin.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Exenatide.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2005 (American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists), a journal based in England.

More context: the Exenatide compound page, all human trials.